The Arrival of CAR T-Cell Therapy—Exploring the Latest Advances and Impact on Patient Care
Ahmed Galal, MD
Professor of Medicine
Duke University School of Medicine
Division of Hematologic Malignancies & Cellular Therapy
Duke Cancer Center
Susan Kuhn, MHSc
Manager, Educational Strategy and Content
Lisa R. Rinehart, MS, ELS
Director, Editorial Services
Kathryn Schaefer, MSN, RN, CPHRM
Senior Manager, Accreditation and Compliance
East Lansing, MI
Edward Allan Racela Sison, MD
Missouri City, TX
Upon completion, participants should be able to:
- Describe the principles of CAR T-cell therapy including the mechanism of action and logistics of administration
- Apply the evolving clinical data regarding CAR T-cell therapy in hematologic malignancies to appropriately select patients and understand its future applicability
- Vigilantly monitor for, promptly identify, and appropriately manage toxicities associated with CAR T-cell therapies
This activity is intended for hematology/oncology physicians, nurses, and pharmacists.
Statement of Need
Although CAR T-cell therapies are associated with robust clinical responses, the relative newness of these therapies, complexity of administration, logistics regarding operation, and unique toxicities may make adoption within clinical practice challenging. To effectively incorporate CAR T-cell therapy into the clinic, hematology/oncology clinicians must increase their understanding of CAR T-cell therapy, improve their ability to identify and refer appropriate patients for treatment, stay current on the rapidly emerging clinical data, and promptly identify and manage adverse events. In addition, many multidisciplinary team members are involved in providing care to patients receiving this type of therapy, therefore optimal care coordination is essential. Thus, education regarding integration of CAR T-cell therapies into treatment decision making for patients with relapsed/refractory B-cell malignancies is required to meet the unique educational needs of hematology/oncology care team members.
Provided by Med-IQ.
Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Med-IQ designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS).
Med-IQ is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
This nursing activity has been approved for up to 1.0 contact hour.
Med-IQ is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.0 contact hour (0.1 CEU) of credit for pharmacists. ACPE # 0476-0000-19-014-H01-P. This application-based activity is designed for all pharmacists.
Nurse practitioners, physician assistants, and other healthcare professionals who successfully complete the activity will receive a Statement of Participation indicating the maximum credits available.
Medium/Method of Participation
This CME/CE activity consists of a 1.0-credit online publication. To receive credit, read the introductory CME/CE material, read the publication, and complete the post-survey, evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly. Pharmacists will have credits uploaded directly to NABP.
Initial Release Date: November 27, 2019
Expiration Date: November 26, 2020
Estimated Time to Complete This Activity: 1 hour
Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as those in any amount occurring within the past 12 months, including those of a spouse/life partner, that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.
The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation.?
Ahmed Galal, MD
Consulting fees/advisory boards: Gilead Sciences, Verastem Oncology
Fees received for promotional/non-CME activities: Celgene Corporation, Gilead Sciences, Incyte Corporation
Susan Kuhn, MHSc
Spouse Ownership interest (stocks/stock options – excluding mutual funds): Illumina, Johnson & Johnson, Viking Therapeutics
Edward Allan Racela Sison, MD
Salary: Covance, Inc.
The peer reviewers and other activity planners have no financial relationships to disclose.
Statement of Evidence-Based Content
Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, Med-IQ has a policy to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.
Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity.
For questions or comments about this activity, please contact Med-IQ. Call (toll-free) 866 858 7434 or email email@example.com.
Operating system - Med-IQ supports the following operating systems:
- Microsoft Windows supported by Microsoft
- Mac OS supported by Apple
Browsers - Med-IQ supports the current version of each browser listed below, plus two prior versions:
Microsoft Internet Explorer
- Microsoft Edge
Operating system - Med-IQ supports the current operating system, plus two prior releases:
- Android (eg, Samsung Galaxy)
- Apple (eg, iPhone/iPad)
Browsers - Med-IQ supports the default browser for the applicable operating system release, plus two prior releases:
- Android (Chrome)
- Apple (Safari)
Applications & Software
PDF Viewer - Adobe Acrobat Reader or Adobe Reader
Adobe Flash Player - Med-IQ supports the current version, plus two prior versions
For technical assistance, please refer to our Support Manual.
The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.
Privacy & Confidentiality
Acknowledgment of Commercial Support
This activity is supported by educational grants from Celgene Corporation and Gilead Sciences.
© 2019 Med-IQ, Inc.
Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.